Study high­lights the FDA’s speed in ap­prov­ing can­cer drugs as a new com­mish looks to rev up re­views

Dur­ing his con­fir­ma­tion hear­ing on Wednes­day Scott Got­tlieb em­pha­sized that he would start his new job as FDA com­mis­sion­er by fo­cus­ing on dif­fer­ent parts of the agency that have lagged in ac­cel­er­at­ing drug re­views. With the pres­i­dent beat­ing the ta­ble for a stream­lined ap­proval process, you can ex­pect some fresh pres­sure from the top to speed things up. And now Got­tlieb — who was al­ready on record on that score — has some ad­di­tion­al da­ta to point to for his ef­fi­cien­cy cam­paign, high­light­ing where the agency has been ef­fec­tive in speed­ing ap­provals and where it might push for faster ac­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.